Introduction {#s1}
============

Photodynamic inactivation (PDI) is based on the use of a non-toxic photosensitizer, which is activated by light of appropriate wavelength. Activation of the photosensitizer through illumination leads to generation of singlet oxygen and free radicals, which are responsible for the cytotoxic effect on the target tissue^\[[@b1]\]^. Corneal crosslinking uses riboflavin as photosensitizer, which is activated by 375 nm UVA-light illumination. A relative low concentration of free oxygen radicals and singlet oxygen is produced following crosslinking as it has low photosensitizing efficacy, and crosslinking is called riboflavin-UVA-PDI^\[[@b2]\]^.

As riboflavin-UVA-PDI has been reported to be capable of killing bacteria both *in vitro*^\[[@b3],[@b4]\]^ and *in vivo*^\[[@b5],[@b6]\]^, it may be a potential option in case of therapy resistant infectious keratitis. Several clinical studies have already reported the effectiveness of crosslinking such as PDI in curing bacterial^\[[@b7],[@b8]\]^ or even acanthamoeba keratitis^\[[@b5]\]^. In contrast, some authors reported on occurrence of early bacterial keratitis ^\[[@b9],[@b10]\]^ or acanthamoeba keratitis^\[[@b11]\]^ after crosslinking therapy. The possible adverse effects of crosslinking on the corneal tissue may be the limits of usage of riboflavin-UVA-PDI in keratitis. Furthermore, crosslinking may also have an impact on activation of keratocytes or even on local immune response to pathogens.

Wollensak *et al.*^\[[@b12]\]^ reported an abrupt cytotoxic effect on porcine keratocytes *in vitro* using collagen crosslinking, and a decrease in viability and an increase of apoptosis of porcine keratocytes^\[[@b13]\]^. The impact of riboflavin-UVA-PDI was also tested in a human keratocyte cell line, which showed significantly decreased cell viability^\[[@b13]\]^. However, properties of immortalized cell lines or porcine cells differ from primary human keratocytes, so we conducted this study to determine the impact of riboflavin-UVA PDI on viability, apoptosis and activation of human primary keratocytes *in vitro*.

Materials and methods {#s2}
=====================

Reagents {#s2a}
--------

Dulbecco\'s Modified Eagle Medium (DMEM/F12), fetal calf serum (10%), P/S (1% of 10,000 U penicillin/10 mg streptomycin per mL), and 0.05% trypsin/0.02% ethylenediaminetetra-acetic acid (EDTA) were purchased from PPA Laboratories (Pasching, Austria). AlamarBlue® was obtained from Invitrogen (Karlsruhe, Germany). Collagenase A and Dispase II were obtained from Roche Diagnostics (Mannheim, Germany). The APO-DIRECT™ kit was from BD Biosciences (Heidelberg, Germany). Mouse anti-human CD34-FITC anti-alpha smooth muscle actin antibody (FITC) was obtained from Biozol (Eching, Germany) and Abcam (Cambridge, USA), respectively. Riboflavin-5-phosphate and Dextran were both purchased from Sigma-Aldrich (Heidelberg, Germany).

Isolation of primary human corneal keratocytes {#s2b}
----------------------------------------------

Human corneas were obtained from the Saarland University Hospital Eye Bank. Keratocytes were isolated as described previously^\[[@b14]\]^. The human corneoscleral buttons were aseptically rinsed in phosphate-buffered saline (PBS) before removal of the endothelium including Descemet\'s membrane by sterile surgical disposable scalpel. A central corneal button with epithelium was cut using a 8.0 mm Barron's trephine and thereafter incubated in culture medium containing 2.4 U/mL Dispase II for 4 hours at 37 °C. Thereafter, the corneal button was washed with PBS for several times and the loose corneal epithelium was removed with surgical disposable scalpel. The remaining corneal stroma was incubated in culture medium with 1.0 mg/mL collagenase A for 8-10 hours at 37 °C. The digested tissues and cells were centrifuged at 800 *g* for 7 minutes and finally resuspended in 1.0 mL basic medium (DMEM/F12) supplemented with 10% FCS and 1% P/S. The cell suspension was seeded in 6-well plates and the medium was changed 24 hours after seeding. Medium was changed every 2 to 3 days until keratocytes reached confluence. The cells were sub-cultured in 25 cm^2^ culture flasks after 5 to 10 days following dispersal with 0.05% trypsin-EDTA for 3 to 5 minutes and passage 4 to 8 of cells was used for experiments.

Riboflavin-UVA PDI {#s2c}
------------------

Human keratocytes were seeded in tissue culture plates and were allowed to grow for 48 hours before photodynamic treatment. For viability, apoptosis, CD34 and α-SMA expression measurements, final 0.05% and 0.1% concentration of riboflavin-5-phospate was diluted using 20% Dextran-PBS, as the 0 and 1% concentration of riboflavin were used in clinical settings. Cells were exposed directly to UVA light (375 nm) for 4.10 minutes (2 J/cm^2^) following wash twice with PBS, and fed with culture medium and cultured at 37°C for 24 hours before measurements.

AlamarBue® assays {#s2d}
-----------------

Cell viability was investigated using the AlamarBue® assay as follows: Human keratocytes were seeded in 24-well cell culture plates at a concentration of 7.5×10^3^ cells/cm^2^. At 24 hours after illumination, AlamarBlue® solution was diluted with culture medium to a final concentration of 10% and 500 µL of the solution was added to each well. AlamarBlue® solution was added to a well without cells as a negative control. Thereafter, all plates were exposed to an excitation wavelength of 560 nm, and the emission at 616 nm was recorded using a 96-well microplate reader (WALLAC 1420 Multilabel Counter, Perkin Elmer, Life Sciences, Wellesley, MA, USA).

Determination of apoptosis {#s2e}
--------------------------

APO-DIRECT™ kit was used to determine the relative number of apoptotic cells. Cells were seeded in 6-well cell culture plates with a concentration of 7.5×10^3^ cells/cm^2^ and exposed to PDI as described above. After 24-hour exposure to PDI, the culture medium was discarded and the cells were trypsinized before centrifugation, and then the cells were suspended in 1% paraformaldehyd at a concentration of 1.0×10^6^ cells/mL and placed on ice for 30-60 minutes. Thereafter, cells were washed twice with PBS and stored for 30 minutes at -20°C following adding 1.0 mL ice cold 70% ethanol. After removing ethanol carefully by aspiration, fixed cells were resuspended twice in 1.0 mL Wash-Buffer. The control cells and the probes were resuspended in 50 µL DNA-Labeling-Solution (FITC marked dUTP) and the cells were washed twice before resuspending the pellet in 500 µL PI/RNase Staining Buffer. Cells were incubated in the dark for at least 30 minutes at room temperature prior to analysis using a FACSCanto flow cytometer (BD Biosciences, Heidelberg, Germany).

Determination of CD34 and α-SMA expression {#s2f}
------------------------------------------

Cells were seeded in 6-well cell culture plates with a final concentration of 4.0×10^3^ cells/cm^2^ and underwent PDI as described above. After 24 hours exposed to PDI, the cells were trypsinized and washed with PBS. To demonstrate α-SMA expression, the cells were incubated with 0.5 mL PERM solution for 10 minutes, and then washed once with PBS followed by incubation with FITC-conjugated mouse monoclonal antibodies (IgG2a) against human α-SMA (100 µg/10^4^ cells) for 30 minutes in the dark at room temperature. For CD34 detection, a FITC-conjugated monoclonal antibody (IgG1) was used directly at a concentration of 200 µg/mL followed by incubation for 30 minutes in the dark at room temperature. To prove the specificity of the staining, isotype control experiment for each primary IgG-subtype antibody was performed. Cells were washed twice with PBS and analyzed using a FACSCanto flow cytometer (BD Biosciences, Heidelberg, Germany), and the evaluation was performed with WinMDI software (Version 2.9).

Statistical analysis {#s2g}
--------------------

The GraphPad Prism 2.01(GraphPad Software Inc., La Jolla, USA) was used for statistical analysis. Data are presented as mean ± standard deviation (SD). Kruskal-Wallis one-way analysis of variance followed by Wilcoxon-Mann-Whitney Test was performed. *P* values below 0.05 were considered statistically significant.

Results {#s3}
=======

Keratocyte viability {#s3a}
--------------------

The results of the AlamarBlue® assays are shown in [***Fig. 1A***](#f01){ref-type="fig"} (*n* = 5). The Kruskal-Wallis one-way analysis of variance indicated a significant *P*-value of \<0.001 between groups with and without UVA-light illumination. With separate use of riboflavin or UVA-light, there was no significant change in the viability of keratocytes compared to controls (*P*\>0.25). Following riboflavin-UVA-PDI, keratocyte viability was significantly decreased in groups treated with 0.05% and 0.1% riboflavin (both *P*\<0.01) compared to controls.

![(A) Viability of keratocytes 24 hours after Photodynamic inactivation (PDI) (Riboflavin).\
Viability of keratocytes were examined by AlamarBlue assays as described in Methods. \*\**P*\<0.01 (B) Apoptosis of keratocytes 24 hours after PDI (Riboflavin).](jbr-29-04-321-g001){#f01}

Furthermore, there was no significant difference in the percentage of apoptotic keratocytes using riboflavin, UVA-light illumination or riboflavin-UVA-PDI compared to controls ([***Fig. 1B***](#f01){ref-type="fig"}, *n* = 6) (*P*=0.581)

CD34 and α-SMA expression in keratocytes {#s3b}
----------------------------------------

CD34 and α-SMA expression of keratocytes 24 hours following PDI is summarized in [***Fig. 2A***](#f02){ref-type="fig"} and [***2B***](#f02){ref-type="fig"} (*n* = 6). CD34 and α-SMA expression between groups treated with and without UVA-light showed a significant difference with *P*-value of 0.004 and 0.012, respectively. CD34 and α-SMA expression in cells treated with riboflavin or UVA did not change significantly compared to controls. Twenty-four hours after riboflavin-UVA-PDI, the expression of CD34 increased significantly in groups treated with 0.05% (8.7% positive) and 0.1% (6.6% positive) riboflavin compared to controls (2.6% positive; *P*\<0.01 for both). The percentage of α-SMA positive keratocytes increased significantly in groups treated with riboflavin-UVA-PDI at 0.05% (35.8% positive, *P*\<0.01) and 0.1% (29.1% α-SMA positive, *P*\<0.05) compared to untreated cells (14.5% positive).

![CD34 (A) and a-SMA (B) expression of keratocytes 24 hours after PDI (Riboflavin).\
\*\**P*\<0.01](jbr-29-04-321-g002){#f02}

Discussion {#s4}
==========

Corneal collagen crosslinking is currently used to reduce or stop the progression of keratoconus^\[[@b8]\]^, or further applied as riboflavin-UVA-PDI, which has a potential to be an alternative therapeutic option in infectious keratitis^\[[@b2]\]^. Even though clinical use of crosslinking started several years ago, this is the first study of illustration of viability, apoptosis and activation using primary human keratocytes following crosslinking/riboflavin-UVA-PDI.

In the present *in vitro* study, we demonstrated that PDI using riboflavin-5-phosphate reduced the viability of primary human keratocytes 24 hours following UVA-illumination, but did not induce cell apoptosis, In our previous experiments, we found significantly decreased viability and increased apoptosis of primary human keratocytes *in vitro* 24 hours after PDI using chlorine e6 as photosensitizer and 675 nm wavelength illumination^\[[@b15]\]^. The decrease of viability and the increase of apoptosis were photosensitizer dose dependent. Chlorin e6 is a photosensitizer with high photosensitizing efficacy, therefore, with more reactive oxygen species production during photodynamic inactivation, compared to riboflavin-UVA-PDI. This may result in a decreased viability and triggered apoptosis of keratocytes at even lower concentrations of the photosensitizer, by the use of chlorine e6-PDI^\[[@b15]\]^.

A study of Dua *et al.*^\[[@b16]\]^ confirmed that CD34 positive keratocytes were multi-potent hematopoietic stem cells. The role of CD34 positive hematopoietic stem cells may be to replenish tissue resident macrophages and plasmacytoid dendritic cells^\[[@b17],[@b18]\]^. A study on CD34 positive corneal cells suggested that they may also play roles in cytoadhesion and signalling related to differentiation and proliferation^\[[@b19]\]^.

Increased α-smooth actin expression was detected in myofibroblasts, but not in keratocytes^\[[@b20]\]^. Corneal myofibroblasts play an important role in corneal wound healing and contraction. Recent studies have shown that corneal myofibroblasts are also involved in bacterial and viral clearance by the expression of toll-like receptors (TLRs), which are receptors for lipopolysaccharides produced by bacteria^\[[@b21]\]^. CD34 expression in human keratocytes was reported to be down-regulated during myofibroblast differentiation^\[[@b22]\]^.

The most conspicuous finding of our study is that not only α-smooth actin expression, but also CD34 expression were triggered 24 hours following riboflavin-UVA-PDI. In other words, crosslinking promoted myofibroblastic transformation and transformation of keratocytes into multi-potent hematopoietic stem cells in short term. This means that the reported early bacterial or even acanthamoeba infections after crosslinking did not occur through suppression of myofibroblastic or hematopoietic stem cell transformation. The use of crosslinking as antimicrobial therapy may be appropriate, because that it may promote instead of suppressing the cellular defense mechanisms against pathogens.

Interestingly, chlorine e6-PDI inhibits myofibroblastic transformation of keratocytes, but does not have an impact on activation of CD34-positive keratocytes^\[[@b23]\]^. The triggered molecular pathways in human cells or even in microorganisms following PDI using distinct photosensitizers needs further analyses.

In conclusion, we confirmed that crosslinking/riboflavin-UVA-PDI decreases viability but does not have an impact on apoptosis of human keratocytes *in vitro*.
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